期刊文献+

FAS-670 A>G基因多态性与宫颈癌发病风险的meta分析

FAS-670 A > G Polymorphism and Risk of Cervical Cancer: a Meta-Analysis
下载PDF
导出
摘要 目的:探讨FAS-670 A> G基因多态性与宫颈癌发病风险的关联。方法:于Pubmed、知网等数据库中全面检索相关文献,收集2016年12月前公开发表的相关文献,使用Stata12. 0进行meta分析。结果:经过严格标准筛选,最终纳入本次meta分析的研究共13项,累计病例3146例,对照3070例。共记录4种模式:纯合子(GG vs AA);显性模式(AG+GG vs AA);隐性模式(GG vs AA+AG);等位基因(G vs A)。在各模式中,meta分析的OR值及95%置信区间分别为1. 00 (0. 78-1. 28); 1. 05 (0. 84-1. 32); 1. 02 (0. 84-1. 25); 1. 02(0. 91-1. 15),且按种族进行亚组分析中各OR值均无统计学意义。结论:FAS-670 A> G基因多态性与宫颈癌发病风险之间无显著性关联。 Objective: In order to Explore the association between FAS -670 A 〉 G polymorphism and the risk of cervical cancer. Methods: the relevant articles published before December 2016 was retrieved from the database of Pubmed and CNKI, and the meta analysis was carried out by Stata 12.0. Results: Thirteen studies, which contended 3146 cases and 3070 controls in total, were finally selected through executing rigid standards. By considering the wild type genotype (AA) or allele (A) as the reference, the ORs and 95 % CIs were calculated separately for 4 genetic models : homozygous ( GG vs AA), dominant ( AG + GG vs AA), recessive model ( GG vs AA + AG) and allele contrast ( G vs A) . In overall meta - analysis, the pooled Ors and their 95% confidence interals were 1.00 (0.78-1.28); 1.05 (0.84-1.32); 1.02 (0.84-1.25); 1.02 (0.91-1.15) .Alsowith the subgroup analysis, there are no significant differences in all models. Conclusion : The FAS - 670 A 〉 G polymorphism might not contribute to the susceptibility of cervical cancer.
作者 杨云 李松柏 张细梅 廖兵荣 张映 YANG Yun1, LI Song- bo1, ZHANG Xi -mei2, LIAO Bing- tong1, ZHANG Ying3(1. Medical School of Yichun University, Institute of Preventive Medicine of Yichun University, Yichun 336000, 2. Department of Nephrology in Jiangxi People's Hospital, Nanchang 330006, China; 3. Cixi Kandun Hospital, Cixi 315303, China)
出处 《宜春学院学报》 2018年第9期56-62,共7页 Journal of Yichun University
关键词 FAS 宫颈癌 基因多态性 META分析 FAS cervical cancer genetic polymorphism Meta - analysis
  • 相关文献

参考文献3

二级参考文献26

  • 1章文华,吴令英,白萍,李淑敏,张蓉,李斌,孙建衡,吴爱如.ⅠB期和ⅡA期宫颈癌患者的预后因素分析[J].中华肿瘤杂志,2004,26(8):490-492. 被引量:41
  • 2林东昕,孙瞳.单体型在肿瘤研究中的应用与展望[J].中华肿瘤杂志,2005,27(5):257-259. 被引量:5
  • 3Humlg QR, Morris D, Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol, 1997, 34:577-582.
  • 4Sibley K, Rollinson S, Allan JM, et al. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res, 2003, 63:4327-4330.
  • 5Wu J, Metz C, Xu X, et al. A novel polymorphic CAAT/enhancerbinding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. Immunol, 2003, 170 : 132-138.
  • 6Wright TC Jr, Schiffman M, Solomon D, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol, 2004, 103:304- 309.
  • 7Sun T, Miao X, Zhang X, et al. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst, 2004, 96:1030-1036.
  • 8Ju ST, Panka DJ, Cui H, et al. Fas( CD95 )/Fas L interactions required for programmed cell death after T-cell activation. Nature, 1995, 373:444-448.
  • 9Krammer PH. CD95's deadly mission in the immune system. Nature, 2000, 407:789-795.
  • 10Kim R, Emi M, Tanabe K, et al. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. Cancer, 2004, 100: 2281- 2291.

共引文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部